Citations

Clear

387 citation(s) found for "Couch, Fergus".

A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers
Powers, Jacquelyn , Pinto, Emília M. , Barnoud, Thibaut , Leung, Jessica C. , Martynyuk, Tetyana , Kossenkov, Andrew V. , Philips, Aaron H., Desai, Heena , Hausler, Ryan , Le, Anh N. , Pyle, Louise C. , Zelley, Kristin , Nathanson, Katherine L. , Slavin, Thomas P. , Weitzel, Jeffrey N. , Stopfer, Jill E. , Offit, Kenneth , Dolinsky, Jill S. , Gutierrez, Stephanie, McGoldrick, Kelly , Levin, Brooke , Edelman, Morris, Levy, Carolyn Fein , Spunt, Sheri L. , Zambetti, Gerard P. , Li, Marilyn M , MacFarland, Suzanne P , Pyle, Louise C , Zelley, Kristin , Domchek, Susan M , Weitzel, Jeffrey N , Garber, J. E. , Joseph, Vijai , Levin, Brooke , Levy, Carolyn Fein , Spunt, Sheri L , Nathanson, Katherine L , Kelly, Gregory, Domchek, Susan M. , Garber, Judy E. , Vijai, Joseph , Couch, Fergus J. , Kriwacki, Richard W. , Ribeiro, Raul C , Murphy, Maureen E. , Maxwell, Kara N.

Mayo Clinic

Cancer Research | July 16, 2020 | Volume: 80 | Issue: 17 | Pages: 3732-3744

10.1158/0008-5472.can-20-1390 | PMID 32675277 Get It

Abstract Germline mutations in TP53 cause a rare high penetrance cancer syndrome, Li–Fraumeni syndrome (LFS). Here, we identified a rare TP53 tetramerization domain missense mutation, c.1000G>C;p.G334R, in a family with multiple late-onset LFS-spectrum cancers. Twenty additional c.1000G>C probands and one c.1000G>A proband were identified, and available tumors showed biallelic somatic inactivation of TP53. The majority of families were of Ashkenazi Jewish descent, and the TP53 c.1000G>C allele was found on a commonly inherited chromosome 17p13.1 haplotype. Transient transfection of the p.G334R allele conferred a mild defect in colony suppression assays. Lymphoblastoid cell lines from the index family in comparison with TP53 normal lines showed that although classical p53 target gene activation was maintained, a subset of p53 target genes (including PCLO, PLTP, PLXNB3, and LCN15) showed defective transactivation when treated with Nutlin-3a. Structural analysis demonstrated thermal instability of the G334R-mutant tetramer, and the G334R-mutant protein showed increased preponderance of mutant conformation. Clinical case review in comparison with classic LFS cohorts demonstrated similar rates of pediatric adrenocortical tumors and other LFS component cancers, but the latter at significantly later ages of onset. Our data show that TP53 c.1000G>C;p.G334R is found predominantly in Ashkenazi Jewish individuals, causes a mild defect in p53 function, and leads to low penetrance LFS. Significance: TP53 c.1000C>G;p.G334R is a pathogenic, Ashkenazi Jewish–predominant mutation associated with a familial multiple cancer syndrome in which carriers should undergo screening and preventive measures to reduce cancer risk.
Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants
Silvestri, Valentina , Group, and the CIMBA, Agnarsson, Bjarni A. , Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L. , Barkardóttir, Rósa B. , Barroso, Alicia, Barrowdale, Daniel , Borg, Åke , Caldés, Trinidad , Claes, Kathleen , Cortesi, Laura , Ding, Yuan Chun , Easton, Douglas F. , Ejlertsen, Bent , Engel, Christoph , Evans, D. Gareth , Feliubadaló, Lídia , Géczi, Lajos , Glendon, Gord , Goldgar, David E. , Hahnen, Eric , Hogervorst, Frans B.L., Hulick, Peter J. , Izquierdo, Á. , James, Paul A. , Jensen, Uffe Birk , John, Esther M. , Konstantopoulou, Irene , Kurian, Allison W. , Kwong, Ava , Landucci, Elisabetta, Lesueur, Fabienne , Loud, Jennifer T. , Macháčková, Eva , Mai, Phuong L., Majidzadeh‐A, Keivan , Manoukian, Siranoush , Montagna, Marco , Nathanson, Katherine L. , Ngeow, Joanne , Ņikitina-Zaķe, Liene , Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I. , Osório, Ana , Park, Sue K. , Pedersen, Inge Søkilde , Petersen, Annabeth Høgh , Pinto, Pedro, Pujana, Miquel Angel, Rantala, Johanna, Rashid, Muhammad Usman , Rosenzweig, Barak , Rossing, Maria , Santamariña, Marta , Schmutzler, Rita K., Simard, Jacques , Solano, Ángela R. , Steele, Linda , Steinsnyder, Zoe , Tan, Yen Y. , Teixeira, Manuel R. , Teo, Soo‐Hwang , Terry, Mary Beth , Thomassen, Mads, Torres‐Esquius, Sara , Tung, Nadine, Vega, Ana , Viel, Alessandra , Vierstraete, Jeroen , Wappenschmidt, Barbara , Weitzel, Jeffrey N. , Wieme, Greet , Yoon, Sook‐Yee , McGuffog, Lesley, Hamann, Ute, Greene, Mark H. , Kirk, Judy A., Chenevix‐Trench, Georgia , Antoniou, Antonis C. , Friedman, Eitan, Durocher, Francine , Pujana, Miguel Ángel , Hulick, Peter J , James, Paul , Lesueur, Fabienne , Pujana, Miquel Angel , Teixeira, Manuel R , Teo, Soo H , Vega, Ana , Weitzel, Jeffrey N , Claes, Kathleen B M , Evans, D Gareth , John, Esther M , Konstantopoulou, Irene , Olopade, Olufunmilayo I , Silvestri, Valentina , Wieme, Greet , Nathanson, Katherine L , Barrowdale, Daniel , Cortesi, Laura , Engel, Christoph , Izquierdo, Angel , Montagna, Marco , Pinto, Pedro , Viel, Alessandra , Simard, Jacques , Chenevix-Trench, Georgia , Kurian, Allison W , Rashid, Muhammad U , Feliubadaló, Lidia , Santamariña, Marta , Ngeow, Joanne , Manoukian, Siranoush , Terry, Mary Beth , Kwong, Ava , Leslie, Goska , Barnes, Daniel R. , Group, and the CIMBA, Benı́tez, Javier , Bonanni, Bernardo , Borg, Åke , Buys, Saundra S. , Caligo, Maria A. , Capalbo, Carlo , Campbell, Ian , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Hoya, Miguel de la , Dı́ez, Orland , Domchek, Susan M. , Foretová, Lenka , Fostira, Florentia , Gerdes, Anne‐Marie , Godwin, Andrew K. , Hopper, John L. , Isaacs, Claudine , Janavičius, Ramūnas , Vijai, Joseph , Mai, Phuong L., Moserle, Lidia , Mulligan, Anna Marie , Nevanlinna, Heli , Olah, Edith, Papi, Laura , Perez-Segura, Pedro , Porfirio, Berardino , Radice, Paolo , Senter, Leigha , Singer, Christian F. , Southey, Melissa C. , Stoppa‐Lyonnet, Dominique , Toland, Amanda Ewart , Tung, Nadine , Asperen, Christi J. van , Zorn, Kristin K. , Parsons, Michael T. , Neuhausen, Susan L. , Rebbeck, Timothy R. , Tischkowitz, Marc D. , Friedman, Eitan, Ottini, Laura

Mayo Clinic

JAMA Oncology | July 2, 2020 | Volume: 6 | Issue: 8 | Pages: 1218

10.1001/jamaoncol.2020.2134 | PMID 32614418 Get It

N-terminal pro-brain natriuretic peptide levels after receipt of anthracycline for breast cancer.
Herrmann, Joerg , Loprinzi, Charles L. , Ruddy, Kathryn J. , Patel, Shruti , Vierkant, Robert A. , Olson, Janet E. , Couch, Fergus J. , Hazim, Antonious

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e24103-e24103

10.1200/jco.2020.38.15_suppl.e24103 Get It

e24103 Background: Many of the 200,000 patients diagnosed with breast cancer (BC) annually in the United States receive anthracycline-based therapy, increasing their risk of future congestive heart failure. N-terminal brain natriuretic peptide (NT-proBNP) has been used as a biomarker of asymptomatic cardiac dysfunction in the general population and is of interest to identify patients who might benefit from echocardiography during survivorship. This study aimed to assess how age, baseline comorbidities, and time since BC diagnosis impact NT-proBNP levels after anthracycline-based chemotherapy. Methods: This retrospective study, using samples collected in our ongoing prospective Mayo Clinic Breast Disease Registry, included 20 survivors of non-metastatic BC patients per year for each of the first 5 years after anthracycline-based chemotherapy (n=100 total). NT-pro-BNP levels were assessed using a Roche immunoassay. Cardiac risk factors were obtained by chart review. Multivariable linear regression models assessed associations between NT-proBNP values and these independent variables: baseline cardiac risk factors (including hypertension, hyperlipidemia, obesity, diabetes mellitus, and smoking), tumor ER status (surrogate for possible endocrine therapy), time between diagnosis and serum collection, T and N status, use of trastuzumab, and age. Results: The mean age at the time of BC diagnosis was 52.2 (SD 9.8). 13% of tumors were human epidermal growth factor receptor (HER2)-positive and 71% were estrogen receptor (ER) positive. NT-proBNP was elevated in 34%. Mean NT-BNP level was higher (p=0.047) for those in years 4-5 (158 pg/mL) compared to those in years 1-3 (106 pg/mL) (See Table.) Models revealed years from diagnosis to serum draw (p=0.026), older age (p=0.006), more cardiac risk factors (p=0.064), and N2-3 (p=0.001) were associated with elevated NT-pro-BNP level. Use of trastuzumab, ER status, and tumor size were not associated with NT-proBNP. Conclusions: NT-proBNP is elevated in 1/3 of survivors who received anthracycline therapy for BC. As expected, cardiac risk factors and advancing age are associated with higher NT-proBNP. NT-proBNP values >300 were only found in patients who were 4-5 years after diagnosis. Additional research will be needed to further define the diagnostic and prognostic merit of NT-proBNP in survivors after receipt of anthracycline therapy. [Table: see text]
Genetic testing experiences and emotional reactions among individuals with variant of uncertain significance results from cancer multiplex genetic testing.
Brower, Jamie , Clark, Dana , Kane, Sarah , Sanchez, Pauleen, Wildman, Temima , Merrill, Margaret S., Offit, Kenneth , Hamilton, Jada G. , Ebrahimzadeh, Jessica , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E. , Domchek, Susan M.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e13680-e13680

10.1200/jco.2020.38.15_suppl.e13680 Get It

e13680 Background: Multiplex genetic testing (MGT) simultaneously analyzes multiple cancer susceptibility genes and can reveal genetic variants of uncertain significance (VUS) that have unclear associations with cancer risks. Little is known about how people are prepared for receiving VUS results from MGT, or whether their emotional reactions differ based on the levels of cancer risk to which they may be susceptible. Methods: We recruited participants from the online Prospective Registry of Multiplex Testing (PROMPT). Those with only a VUS in a cancer predisposition gene completed a survey including measures of their MGT experience, distress (range 0-30; α = .87), uncertainty (0-45; α = .83), and positive experiences (0-20; α = .75). We used generalized linear modeling to examine how demographics, awareness of the possibility of VUS before testing, and level of cancer risks associated with their VUS gene were related to emotional outcomes. Results: Data were available from 661 individuals (40% response rate, 95% female, 90% white, 78% college graduate, 69% cancer history, age 23-93) with VUS in a gene of high risk (47%), moderate/low risk (35%) or limited evidence of risk (18%). Among the sample, 80.8% reported ever receiving cancer genetic counseling, and only 50.8% reported being aware of the possibility of VUS when deciding about testing. Participants reported low current distress ( M± SD= 3.25±5.19), uncertainty (9.18±8.35) and positive experiences (7.83±5.98). Distress was associated with younger age, less family cancer history, and being unaware of the possibility of VUS before testing; distress was also higher among those with VUS in a gene of high risk than those with VUS in a gene of moderate/low risk or limited evidence of risk ( ps≤.023). Uncertainty was associated with younger age, non-white race, less education, and being unaware of the possibility of VUS; uncertainty was also higher among those with VUS in a gene of high risk than those with VUS in a gene with limited evidence of risk ( ps≤.05). Fewer positive experiences were associated with more education and more family cancer history; those with VUS in a gene of high risk had fewer positive experiences than those with VUS in a gene with limited evidence of risk ( ps≤.03). Conclusions: Many individuals undergoing MGT may not fully understand the prospect of receiving VUS. Clinicians should consider patients’ background, preparation, and level of cancer risk to which they are potentially susceptible, as these factors may affect their emotional adaptation.
Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).
Brower, Jamie , Symecko, Heather , Marcell, Vanessa , Walsh, Michael F. , Offit, Kenneth , Domchek, Susan M. , Hamilton, Jada G. , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 1508-1508

10.1200/jco.2020.38.15_suppl.1508 Get It

1508 Background: With the expansion of multigene panel testing for cancer susceptibility, increasing numbers of patients are identified with pathogenic/likely pathogenic variants (P/LP V) in genes which do not have a clearly actionable increased risk of ovarian cancer (OC) (lifetime risk of OC >5%). However, there is concern that patients and/or providers may ascribe OC risk to such genetic findings with the potential for unnecessary oophorectomy (ooph). Methods: The Prospective Registry of Multiplex Testing (PROMPT) is an online registry for individuals with a genetic alteration detected on multiplex panel testing for cancer susceptibility. Participants self-enroll and complete baseline and annual follow-up questionnaires. PROMPT has enrolled 7388 participants (6936; 93.9% women) since September 2014. Results: 1566 women in the PROMPT registry reported ooph, the indications for which were reported as either cancer treatment (n=481, 30.7%) or benign disease (n=432, 27.6%). An additional 186 (12.8%) reported PV in genes associated with lifetime OC risk >5% ( BRCA1, BRCA2, RAD51C, RAD51D, BRIP, or Lynch syndrome genes). The remaining 467 did not have guideline based indications for ooph due to OC risk and are described further here. 92 (19.7%) had a variant of uncertain significance (VUS) in genes associated with OC, 241 (51.6%) had a personal history of breast cancer (BC) and no VUS in OC genes, and 119 (25.5%) had no personal history of BC and no VUS in OC genes. The majority of women had no family history (FH) of OC in first or second degree relatives (Table). Most ooph occurred prior to age 50. Of the 405 women with CHEK2 P/LP, 11.4% reported ooph (59% under age 50 when age known), as did 13.2% (of 228) with CHEK2 VUS, 8.8% (of 261) with ATM P/LP (66.7% under age 50), and 8.3% (of 387) with ATM VUS. In addition, of the 184 women with PALB2 P/LP, 14.1% reported ooph (35.3% under age 50) as did 11.6% (of 198) with PALB2 VUS. Of those who reported provider discussions, 47.2% stated “my provider recommended this” (including >60% in the OC gene VUS group) and an additional 25.2% stated “my provider presented this as an option, but not a requirement”. In those with no FH of OC, 45.8% stated that their provider recommended ooph. Conclusions: 10-15% of women with PV/VUS in genes not associated with a high risk of OC reported ooph without a clear indication. [Table: see text]
Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.
Fasching, Peter A. , Gelpí, Judith Balmaña, McCutcheon, Susan , Ano, Sabine, O’Shaughnessy, Joyce , Gelmon, Karen A. , Couch, Fergus J. , Delaloge, Suzette , Labidi‐Galy, Sana Intidhar , Bennett, James

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 1087-1087

10.1200/jco.2020.38.15_suppl.1087 Get It

1087 Background: OlympiAD (NCT02000622) demonstrated the benefit of olaparib over standard of care in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC) and germline BRCA mutations (gBRCAm). LUCY (NCT03286842) aimed to provide additional data on the real-world effectiveness and safety of olaparib monotherapy in this setting. Methods: This Phase IIIb, open-label, single-arm study of olaparib 300 mg twice-daily, enrolled pts with HER2- gBRCAm MBC who had received a taxane and/or anthracycline in the (neo)adjuvant/metastatic setting, and ≤2 lines of chemotherapy for MBC. Hormone receptor-positive (HR+) pts had progressed on prior endocrine therapy (ET), and further ET was considered unsuitable. Primary endpoint: investigator-defined progression-free survival (PFS). Secondary endpoints: overall survival, time to first subsequent therapy or death (TFST), and investigator-assessed clinical response rate (CRR). The interim analysis was planned after 160 PFS events. Results: From Oct 2018-Sept 2019, 252 pts were enrolled (160 sites, 15 countries; mean age 46.2 [range 22-75] years; 73.4% ECOG PS 0). Median total treatment duration: 7.9 months (mo; range 0.2-20.0). Median PFS: 8.1 mo (95% confidence interval [CI] 6.9, 8.7; 166 events [65.9%]). Clinical trial information: NCT03286842 . Median TFST: 9.7 mo (95% CI 8.7, 11.1). CRR: 48.6% (95% CI 42.2, 55.0). Adverse events (AEs) in >20% of pts (all grades): nausea, anemia, asthenia, vomiting, and fatigue. 24.6% of pts reported a grade ≥3 AE, including anemia (n=33 [13.1%]). 4.4% of pts had an AE leading to treatment discontinuation. Conclusions: Interim results in this real-world population of pts with HER2- gBRCAm MBC were consistent with the OlympiAD study, and support olaparib as a chemotherapy-free alternative treatment for pts with gBRCAm advanced BC. [Table: see text]
Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.
Chumsri, Saranya , Ma, Yaohua , Hinerfeld, Douglas, Brauer, Heather Ann , Warren, Sarah , Perez, Edith A. , Leon‐Ferre, Roberto A. , Liu, Minetta C. , Knutson, Keith L. , Thompson, E. Aubrey , Carter, Jodi M. , Nielsen, Torsten O. , Asleh, Karama , Joensuu, Heikki , Hillman, David W. , Boughey, Judy C. , Ingle, James N. , Kalari, Krishna R. , Couch, Fergus J. , Knutson, Keith L. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 510-510

10.1200/jco.2020.38.15_suppl.510 Get It

510 Background: Several studies have established the critical role of preexisting immune response in triple negative breast cancer (TNBC). Most studies evaluated the tumor infiltrating lymphocytes in stroma. However, limited data are available with regards to the importance of specific subtypes and spatial distribution of these immune infiltrates. Methods: NanoString IO360 gene expression analysis and Digital Spatial Profiling (DSP) were used. DSP was used to quantify 39 immune-related proteins in stromal and tumor-enriched segments from 44 TNBC samples from the FinXX trial (NCT00114816) and 335 samples from the Mayo Clinic (MC) cohort of centrally reviewed TNBC (Leon-Ferre BCRT 2018). In FinXX trial, 22 patients with recurrence and 22 patients without recurrence were included. In MC cohort, 217/335 patients received adjuvant chemotherapy while 118 patients had surgery only without adjuvant chemotherapy. Regions were segmented based on pancytokeratin staining. The general linear model was used for statistical analysis of differential expression with recurrence free survival (RFS) as a categorical variable (recur yes or no). Kaplan-Meier estimates and Cox regression models were also used for analysis. Results: In the FinXX trial, using global gene expression analysis with IO360, there was no signature significantly associated with RFS. However, using DSP, high protein expression of CD56 in the tumor-enriched segments was associated with significant improvement in RFS (HR 0.26, 95%CI 0.09-0.78, p 0.01). Nevertheless, CD56 expression in the stroma (HR 0.66, 95%CI 0.29-1.53, p 0.33) and all segments (HR 0.53, 95%CI 0.23-1.25, p 0.14) was not significantly associated with improved outcome. We further validated these findings in the MC TNBC cohort where intratumoral CD56 expression was associated with a significant improvement in RFS (HR 0.23, p 0.002) but not stromal CD56 (p 0.79). Interestingly, when evaluating the MC TNBC cohort according to receipt of chemotherapy, intratumoral CD56 was associated with improved outcome only in patients who received chemotherapy (p 0.02 vs. 0.07). In both cohorts, higher expressions of intratumoral PD-L1, HLA-DR, and CD8 were associated with improved outcome. Conclusions: Using an in-depth analysis with spatially defined context, we identify that intratumoral CD56-positive NK cells are associated with improved outcome in TNBC. Our study highlights the potential role of NK cells in TNBC and future implications for biomarkers and therapeutic targets.Support: W81XWH-15-1-0292, P50CA116201-9, P50CA015083. Clinical trial information: NCT00114816 .
Mutation prevalence tables for hereditary cancer derived from multigene panel testing
Hart, Steven N. , Yussuf, Amal , Yadav, Siddhartha , Goldgar, David E. , Hu, Chunling , LaDuca, Holly , Smith, Laura P., Fujimoto, June, Li, Shuwei , Dolinsky, Jill S. , Polley, Eric C. , Yadav, Siddhartha , Hart, Steven N , Hu, Chunling , Couch, Fergus J.

Mayo Clinic

Human Mutation | May 22, 2020 | Volume: 41 | Issue: 8 | Pages: No page available

10.1002/humu.24053 | PMID 32442341 Get It

Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk
Middha, Pooja , Choudhury, Parichoy Pal , Wilcox, Amber N , Lindström, Sara , Behrens, Sabine , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin , Jung, Audrey , Abu‐Ful, Zomoroda, Andrulis, Irene L. , Aronson, Kristan J. , Auer, Paul L. , Becher, Heiko , Beckmann, Matthias W. , Beeghly‐Fadiel, Alicia, Bojesen, Stig E. , Brauch, Hiltrud , Brenner, Hermann , Brüning, Thomas , Campa, Daniele , Carracedo, Ángel , Carter, Brian D., Castelao, Jose E. , Chatterjee, Nilanjan , Chenevix‐Trench, Georgia , Cox, Angela , Earp, H. Shelton , Ekici, Arif B. , Eliassen, A. Heather , Eriksson, Mikael , Evans, D. Gareth , Fasching, Peter A. , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , Gao, Chi , Gapstur, Susan M. , Gaudet, Mia M. , González‐Neira, Anna , Guénel, Pascal , Haeberle, Lothar, Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute, Hatse, Sigrid , Holleczek, Bernd , Hoover, Robert N. , Hopper, John L. , Hunter, David J. , Investigators, ABCTB, Investigators, kConFab/AOCS, John, Esther M. , Jones, Michael E. , Kaaks, Rudolf, Keeman, Renske , Ko, Yon-Dschun, Koutros, Stella , Kurian, Allison W. , Lambrechts, Diether , Lee, Eunjung , Lejbkowicz, Flavio, Linet, Martha S. , Lissowska, Jolanta , Llaneza, Ana, MacInnis, Robert J. , Martinez, Maria Elena, Maurer, Tabea, Newman, William G, Orr, Nick , Perou, Charles M. , Pita, Guillermo , Prentice, Ross L. , Rennert, Gad , Rennert, Hedy S., Ruddy, Kathryn J. , Schoemaker, Minouk J. , Scott, Rodney J. , Smeets, Ann , Spinelli, John J. , Stone, Jennifer , Taylor, Jack A. , Vachon, Celine M. , Veen, Elke M. van , Weltens, Caroline , Yang, Xiaohong R. , Easton, Douglas F. , García‐Closas, Montserrat , Chang‐Claude, Jenny, Newman, William G. , Lambrechts, Diether , Norman, Aaron, Polley, Eric C. , Lambrechts, Diether , Rennert, Gad , Behrens, Sabine , Lissowska, Jolanta , Evans, D Gareth , John, Esther M , Maclnnis, Robert , Perou, Charles M , Jones, Michael E , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Gago-Dominguez, Manuela , Guénel, Pascal , Kapoor, Pooja Middha , Koutros, Stella , Newman, William G , García-Closas, Montserrat , Ekici, Arif B , Michailidou, Kyriaki , Taylor, Jack A , Chenevix-Trench, Georgia , Kurian, Allison W , Eriksson, Mikael , Figueroa, Jonine D , Jung, Audrey Y , Becher, Heiko , Eliassen, A Heather , Gabrielson, Marike , Håkansson, Niclas , Stone, Jennifer , Bojesen, Stig E , Schoemaker, Minouk J , Wang, Qin , Brauch, Hiltrud , Orr, Nick , Mavaddat, Nasim , Hurson, Amber N. , Dennis, Joe , Ahearn, Thomas U. , Anton‐Culver, Hoda , Arndt, Volker , Freeman, Laura E. Beane , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Bernstein, Leslie , Cai, Qiuyin , Canzian, Federico , Chanock, Stephen Jacob , Clarke, Christine L. , Couch, Fergus J. , Cross, Simon S. , Czene, Kamila , Dai, James Y. , Fritschi, Lin , Giles, Graham G. , Hall, Per N , Heyworth, Jane , Howell, Anthony , Investigators, ABCTB, Investigators, kConFab/AOCS, Kitahara, Cari M. , Ko, Yon‐Dschun, Marchand, Loı̈c Le , McLean, Catriona , Neuhausen, Susan L. , Norman, Aaron D. , O’Brien, Katie M. , Olshan, Andrew F. , Olson, Janet E. , Olsson, Håkan , Sandler, Dale P. , Saunders, Christobel , Schöttker, Ben , Schumacher, Fredrick R. , Scott, Christopher G. , Shu, Xiao‐Ou , Southey, Melissa C. , Swerdlow, Anthony J. , Tamimi, Rulla M. , Troester, Melissa A. , Vachon, Celine M. , Wang, Xiaoliang , Weinberg, Clarice R. , Willett, Walter C. , Winham, Stacey J. , Wolk, Alicja , Zheng, Wei , Ziogas, Argyrios , Dunning, Alison M. , Pharoah, Paul D.P. , Schmidt, Marjanka K. , Kraft, Peter , Milne, Roger L.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 23, 2020 | Volume: 113 | Issue: 3 | Pages: 329-337

10.1093/jnci/djaa056 | PMID 32359158 Get It

Abstract We evaluated the joint associations between a new 313-variant PRS (PRS313) and questionnaire-based breast cancer risk factors for women of European ancestry, using 72 284 cases and 80 354 controls from the Breast Cancer Association Consortium. Interactions were evaluated using standard logistic regression and a newly developed case-only method for breast cancer risk overall and by estrogen receptor status. After accounting for multiple testing, we did not find evidence that per-standard deviation PRS313 odds ratio differed across strata defined by individual risk factors. Goodness-of-fit tests did not reject the assumption of a multiplicative model between PRS313 and each risk factor. Variation in projected absolute lifetime risk of breast cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history) and, on average, 17.5% higher in the highest vs lowest deciles of genetic risk. These findings have implications for risk prevention for women at increased risk of breast cancer.
Abstract PD3-03: Impact of the breast cancer polygenic risk score on preventive endocrine therapy adherence and endocrine therapy usage on quality of life - The Genetic Risk Estimate (GENRE) trial
Pruthi, Sandhya , Schaid, Daniel J. , Cooke, Andrew , Grenier, Debjani, Vachon, Celine M. , Kim, Julian O. , Kim, Christina , Goldenberg, Benjamin A. , Sinnwell, Jason P. , Couch, Fergus J. , Vachon, Celine M.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: PD3-03-PD3-03

10.1158/1538-7445.sabcs19-pd3-03 Get It

Abstract Background: Studies demonstrate breast cancer risk reduction of 50-65% with the use of endocrine therapy (ET) and yet drug uptake and adherence in this setting is suboptimal even among high risk women. A Polygenic Risk Score (PRS) comprised of 77 BC genetic susceptibility loci (Single Nucleotide Polymorphisms (SNP)) can provide a personalized risk assessment and potentially influence ET adherence. We assessed ET adherence at 1 year comparing women whose risk estimate increased due to PRS versus women whose risk estimate decreased due to PRS. The effect of ET use on quality of life (hot flashes, night sweats, vaginal dryness, weight gain, joint pain) was evaluated. Methods: Eligible women required either a 5 year Gail Model risk of ≥3% or 10 year IBIS ( International Breast Intervention Study or Tyrer-Cuzick model) of ≥5%. Women with a history of breast cancer (BC) or hereditary BC syndrome were excluded. High risk women were counseled at baseline using their Gail and IBIS risk scores and ET options were discussed including benefits and risks. Participants completed a self-reported questionnaire at baseline to assess their understanding of breast cancer risk and decision to take preventive ET. Blood samples were obtained and genotyped for 77 SNPs, and the odds ratio from the SNPs were used to modify the IBIS and Gail risk estimates. The BC -PRS risk estimate information was shared with study participants that reflected the IBIS and Gail risk estimates for 5 year, 10 year, & lifetime BC risk with and without the PRS. Follow up questionnaires at year 1 were administered to assess drug adherence and ET usage on quality of life. Results: 151 women were enrolled at Mayo Clinic Rochester and CancerCare Manitoba from 2016 to 2017. The median age was 56.1 (range 36-76.4), 35.6% were premenopausal, 98.7% were Caucasian and 64.7% had>1 family member with BC. Median 5yr, 10yr, & lifetime IBIS- PRS risk estimates were 3.8% (2.0-11.5), 7.9% (5.0-23.1), and 25.3% (5.5 to 92.2). At year 1 (n=112 women) 46 % of those with an increase in risk when considering the BC-PRS score and 16 % with a decrease in risk were taking ET ( p< 0.001). Types of ET taken: tamoxifen-18, raloxifene- 3, exemestane -14 and missing-1. Women taking ET reported weight gain ( 19.4% vs 6.7%, p=0.04) and more joint pain ( 27.8 % vs 12%, p=0.04) when compared to women not taking ET. Conclusion: In high risk women, BC-PRS risk estimates in addition to standard BC risk calculators had a significant impact on preventive ET adherence. ET use was associated with weight gain and joint pain. Citation Format: Sandhya Pruthi, Julian O Kim, Daniel Schaid, Andrew Cooke, Christina Kim, Benjamin Goldenberg, Jason Sinnwell, Debjani Grenier, Fergus Couch, Celine Vachon. Impact of the breast cancer polygenic risk score on preventive endocrine therapy adherence and endocrine therapy usage on quality of life - The Genetic Risk Estimate (GENRE) trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD3-03.